<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3762">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04709120</url>
  </required_header>
  <id_info>
    <org_study_id>ACTIV-2</org_study_id>
    <nct_id>NCT04709120</nct_id>
  </id_info>
  <brief_title>Analysis of Health Status of Сomorbid Adult COVID-19 Patients Hospitalised in Second Wave of SARS-CoV-2 Infection</brief_title>
  <acronym>ACTIV-2</acronym>
  <official_title>Analysis of Health Status of Сomorbid Adult COVID-19 Patients Hospitalised in Second Wave of SARS-CoV-2 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eurasian Association of Therapists</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eurasian Association of Therapists</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison of COVID-19 disease course in hospitalized patients infected by SARS-CoV-2 in&#xD;
      first and second waves of the novel coronavirus infection&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 11, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>4 Weeks</target_duration>
  <primary_outcome>
    <measure>death</measure>
    <time_frame>4 weeks</time_frame>
    <description>death for any reason</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of cases of Acute Kidney Injury depending on Coexisting Conditions</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of cases of Myocarditis and Acute Coronary Events depending on Coexisting Conditions</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of cases of Cytokine Storm depending on Coexisting Conditions</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of thrombotic and thromboembolic complications of COVID-19 depending on Coexisting Conditions</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decline in GFR excluding Acute Kidney Injury by the time of discharge depending on Coexisting Conditions</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of cases of health status worsening occured during hospitalisation</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">2500</enrollment>
  <condition>Covid19</condition>
  <condition>Comorbidities and Coexisting Conditions</condition>
  <condition>Risk Factor, Cardiovascular</condition>
  <condition>Death</condition>
  <condition>Diabetes</condition>
  <condition>COPD</condition>
  <condition>Atrial Fibrillation</condition>
  <condition>DVT</condition>
  <condition>CKD</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Anonymized male and female patients over the age of 18 hospitalised since October, 1st,&#xD;
        2020&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Suspected or confirmed COVID-19 (according to results of swab-test, antibody test, computed&#xD;
        tomography or radiography image)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Unwillingness to participate in the study;&#xD;
&#xD;
          2. Age under 18.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Grigoriy Arutyunov, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Eurasian Association of Therapists</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ekaterina Tarlovskaya, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Eurasian Association of Therapists</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aleksander Arutyunov, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eurasian Association of Therapists</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tamara Kriukova, master</last_name>
    <phone>+79992114977</phone>
    <email>tk@euat.ru</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anastasia Ermilova</last_name>
    <phone>+79851593410</phone>
    <email>aermilova@euat.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Eurasian Association of Therapists</name>
      <address>
        <city>Moscow</city>
        <zip>101000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamara Kriukova</last_name>
      <phone>+79992114977</phone>
      <email>tk@euat.ru</email>
    </contact>
    <contact_backup>
      <last_name>Anastasia Rud</last_name>
      <phone>+79263639827</phone>
      <email>rud@euat.ru</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 13, 2021</study_first_submitted>
  <study_first_submitted_qc>January 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2021</study_first_posted>
  <last_update_submitted>January 14, 2021</last_update_submitted>
  <last_update_submitted_qc>January 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Eurasian Association of Therapists</investigator_affiliation>
    <investigator_full_name>Tamara Kriukova</investigator_full_name>
    <investigator_title>Eurasian Association of Therapists</investigator_title>
  </responsible_party>
  <keyword>Covid19</keyword>
  <keyword>Comorbidities and Coexisting Conditions</keyword>
  <keyword>Risk Factor</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>COVID-19 Second Wave</keyword>
  <keyword>COVD-19 First Wave</keyword>
  <keyword>Death</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

